Literature DB >> 17482718

The place of guidelines in hospital-acquired pneumonia.

R Masterton1.   

Abstract

The recent increase in hospital-acquired infections (HAIs) has meant that hospital-acquired pneumonia (HAP) has come under the spotlight. HAP is the most common HAI contributing to death and affects about 0.5-1% of all patients admitted to hospital. HAP significantly increases health complications and extends the length of time patients stay in hospital by up to 13 days on average, thus impacting significantly on hospital resources. The British Society of Antimicrobial Chemotherapy Hospital-Acquired Pneumonia guidelines were published on the society's website last year and represent one of only two sets of evidence-based HAP guidelines in the world which deal with the trio of prevention, diagnosis and treatment. This paper reviews the evolution and status of HAP guidelines, drawing attention to recent developments, differences in approach and outcomes and further areas of work. There are clear indications that the implementation of evidence-based guidelines will reduce HAP and improve patient outcomes.

Entities:  

Mesh:

Year:  2007        PMID: 17482718     DOI: 10.1016/j.jhin.2007.03.008

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  2 in total

1.  A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.

Authors:  Samir S Awad; Alejandro H Rodriguez; Yin-Ching Chuang; Zsuszanna Marjanek; Alex J Pareigis; Gilmar Reis; Thomas W L Scheeren; Alejandro S Sánchez; Xin Zhou; Mikaël Saulay; Marc Engelhardt
Journal:  Clin Infect Dis       Date:  2014-04-09       Impact factor: 9.079

Review 2.  Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy.

Authors:  R G Masterton; A Galloway; G French; M Street; J Armstrong; E Brown; J Cleverley; P Dilworth; C Fry; A D Gascoigne; Alan Knox; Dilip Nathwani; Robert Spencer; Mark Wilcox
Journal:  J Antimicrob Chemother       Date:  2008-04-29       Impact factor: 5.790

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.